| 1 Leaving the study early: 1. Any reason |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1 long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
0.95 [0.85, 1.05] |
| 2 Leaving the study early: 2. Due to adverse events |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.1 long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
1.01 [0.65, 1.58] |
| 3 Leaving the study early: 3. Due to relapse / worsening or no improvement |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 3.1 long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
1.05 [0.75, 1.46] |
| 4 Adverse events: Movement disorders (completer‐only data) |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 akathisia ‐ long term |
1 |
399 |
Risk Ratio (M‐H, Random, 95% CI) |
0.75 [0.38, 1.49] |
| 4.2 EPS ‐ long term |
1 |
395 |
Risk Ratio (M‐H, Random, 95% CI) |
1.56 [0.62, 3.94] |
| 4.3 tardive dyskinesia ‐ long term |
1 |
363 |
Risk Ratio (M‐H, Random, 95% CI) |
1.21 [0.73, 2.02] |
| 5 Other adverse events: 1. Arousal |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 5.1 insomnia ‐ long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
0.84 [0.62, 1.13] |
| 5.2 sleepiness/ sedation ‐ long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
1.17 [0.85, 1.60] |
| 6 Other adverse events: 2. Cardiovascular |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 6.1 faintness, dizziness, weakness ‐ long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
0.86 [0.52, 1.42] |
| 7 Other adverse events: 3. Gastrointestinal |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 7.1 weight gain ‐ long term |
1 |
404 |
Risk Ratio (M‐H, Random, 95% CI) |
1.60 [0.84, 3.04] |
| 8 Other adverse events: 4. Genitourinary |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 8.1 diminished sexual desire ‐ long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
1.30 [0.90, 1.87] |
| 8.2 galactorrhea/ gynaecomastia ‐ long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
0.47 [0.14, 1.65] |
| 9 Other adverse events: 5. Others |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 9.1 urinary hesitancy, dry mouth, constipation ‐ long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
1.09 [0.76, 1.58] |
| 9.2 suicide attempt ‐ long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
0.71 [0.04, 11.26] |
| 9.3 incontinence nocturia ‐ long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
0.43 [0.16, 1.15] |
| 10 Other adverse events: 6. any serious adverse event |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 10.1 long term |
1 |
446 |
Risk Ratio (M‐H, Random, 95% CI) |
1.08 [0.63, 1.87] |
| 11 Other adverse events: 7. lab data |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 11.1 mean weight change (lb) ‐ long term |
1 |
446 |
Mean Difference (IV, Random, 95% CI) |
‐0.40 [‐3.45, 2.65] |
| 11.2 change in blood glucose ‐ long term |
1 |
446 |
Mean Difference (IV, Random, 95% CI) |
2.90 [‐5.69, 11.49] |
| 11.3 change in glycosylated haemoglobin ‐ long term |
1 |
446 |
Mean Difference (IV, Random, 95% CI) |
0.20 [‐0.10, 0.50] |
| 11.4 change in cholesterol ‐ long term |
1 |
446 |
Mean Difference (IV, Random, 95% CI) |
9.7 [‐1.44, 20.84] |
| 11.5 change in triglycerides ‐ long term |
1 |
446 |
Mean Difference (IV, Random, 95% CI) |
26.40 [‐2.71, 55.51] |
| 11.6 change in prolactin ‐ long term |
1 |
446 |
Mean Difference (IV, Random, 95% CI) |
4.9 [0.33, 9.47] |
